You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetoprofen
Accession NumberDB01009  (APRD01059, DB05823, DB05335)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionKetoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Structure
Thumb
Synonyms
2-(3-Benzoylphenyl)propionic acid
3-Benzoyl-alpha-methylbenzeneacetic acid
3-Benzoyl-α-methylbenzeneacetic acid
3-Benzoylhydratropic acid
Ketoprofen
L'Acide (benzoyl-3-phenyl)-2-propionique
m-Benzoylhydratropic acid
Orudis (tn)
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KetoprofenCapsule50 mgOralAa Pharma Inc1989-12-31Not applicableCanada
Ketoprofen SRTablet, extended release200 mgOralAa Pharma Inc1995-12-31Not applicableCanada
Ketoprofen SuppositoriesSuppository50 mgRectalPharmel IncNot applicableNot applicableCanada
Ketoprofen SuppositoriesSuppository100 mgRectalPharmel Inc1998-06-04Not applicableCanada
Ketoprofen-ETablet, delayed release100 mgOralAa Pharma Inc1989-12-31Not applicableCanada
Ketoprofen-ETablet, delayed release50 mgOralAa Pharma Inc1989-12-31Not applicableCanada
Ketoprofen-E Ect 100mgTablet, delayed release100 mgOralPro Doc Limitee1996-12-312009-07-23Canada
Ketoprofen-E Ect 50mgTablet, delayed release50 mgOralPro Doc Limitee1995-12-312009-07-23Canada
Ketoprofen-SR - Srt 200mgTablet, extended release200 mgOralPro Doc Limitee1997-09-182009-07-23Canada
Novo-keto Suppositories 100mgSuppository100 mgRectalNovopharm Limited1996-12-312005-08-10Canada
Novo-keto-EC Tab 100mgTablet, delayed release100 mgOralNovopharm Limited1992-12-312005-08-10Canada
Novo-keto-EC Tab 50mgTablet, delayed release50 mgOralNovopharm Limited1992-12-312005-08-10Canada
Nu-ketoprofen Cap 50mgCapsule50 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-ketoprofen-E Ect 100mgTablet, delayed release100 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Nu-ketoprofen-E Ect 50mgTablet, delayed release50 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Orafen - Sup RT 100mgSuppository100 mgRectalTechnilab Pharma Inc.1996-12-312004-08-03Canada
Orudis 100Suppository100 mgRectalAventis Pharma Inc1979-12-312003-07-22Canada
Orudis 50Suppository50 mgRectalAventis Pharma Inc1991-12-312003-07-22Canada
Orudis Cap 50mgCapsule50 mgOralAventis Pharma Inc1979-12-312004-07-30Canada
Orudis E-100Tablet, delayed release100 mgOralAventis Pharma Inc1987-12-312003-07-22Canada
Orudis E-50Tablet, delayed release50 mgOralAventis Pharma Inc1983-12-312004-07-30Canada
Orudis SR-200Tablet, extended release200 mgOralAventis Pharma Inc1988-12-312005-08-01Canada
Oruvail 150Capsule, extended release150 mgOralAventis Pharma Inc1991-12-312003-07-22Canada
Oruvail 200Capsule, extended release200 mgOralAventis Pharma Inc1991-12-312003-07-22Canada
PMS-ketoprofenSuppository50 mgRectalPharmascience Inc1995-12-31Not applicableCanada
PMS-ketoprofenSuppository100 mgRectalPharmascience Inc1993-12-31Not applicableCanada
PMS-ketoprofen CapsulesCapsule50 mgOralPharmascience Inc1995-12-31Not applicableCanada
PMS-ketoprofen E-100 - EctTablet, delayed release100 mgOralPharmascience Inc1995-12-31Not applicableCanada
PMS-ketoprofen E-50 - Ect 50mgTablet, delayed release50 mgOralPharmascience Inc1995-12-31Not applicableCanada
RhodisSuppository100 mgRectalSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhodis Cap 50mgCapsule50 mgOralRhodiapharm Inc1988-12-312005-08-01Canada
Rhodis ECTablet, delayed release50 mgOralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhodis ECTablet, delayed release100 mgOralSanofi Aventis Canada Inc1988-12-312007-01-11Canada
Rhodis SR 200mgTablet, extended release200 mgOralRhodiapharm Inc1995-12-312005-08-01Canada
Rhovail 150Capsule, extended release150 mgOralRhodiapharm Inc1995-12-312005-08-01Canada
Rhovail 200Capsule, extended release200 mgOralRhodiapharm Inc1995-12-312005-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KetoprofenCapsule50 mg/1OralRebel Distributors Corp2010-04-20Not applicableUs
KetoprofenCapsule50 mg/1Oralbryant ranch prepack2011-01-18Not applicableUs
KetoprofenCapsule50 mg/1OralTeva Pharmaceuticals USA Inc1993-01-01Not applicableUs
KetoprofenCapsule50 mg/1OralPhysicians Total Care, Inc.1997-02-14Not applicableUs
KetoprofenCapsule50 mg/1OralAv Kare, Inc.2013-07-082016-03-11Us
KetoprofenCapsule50 mg/1OralPreferred Pharmaceuticals Inc.2016-05-31Not applicableUs
KetoprofenCapsule, extended release200 mg/1OralMylan Pharmaceuticals Inc.2003-09-04Not applicableUs
KetoprofenCapsule50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-04-20Not applicableUs
KetoprofenCapsule75 mg/1OralRebel Distributors Corp2010-04-20Not applicableUs
KetoprofenTablet75 mg/1OralRed Pharm Drug Inc.2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1OralTeva Pharmaceuticals USA Inc1993-01-01Not applicableUs
KetoprofenCapsule75 mg/1OralPhysicians Total Care, Inc.2005-08-15Not applicableUs
KetoprofenCapsule75 mg/1OralAv Kare, Inc.2013-07-082016-03-11Us
KetoprofenCapsule50 mg/1OralAidarex Pharmaceuticals LLC1993-01-01Not applicableUs
KetoprofenCapsule75 mg/1OralProficient Rx LP1993-01-01Not applicableUs
KetoprofenCapsule50 mg/1OralSTAT Rx USA LLC2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1OralAidarex Pharmaceuticals LLC1993-01-01Not applicableUs
KetoprofenCapsule75 mg/1OralPreferred Pharmaceuticals, Inc.2011-01-18Not applicableUs
KetoprofenCapsule50 mg/1OralMylan Pharmaceuticals Inc.1997-01-15Not applicableUs
KetoprofenCapsule, extended release200 mg/1OralPhysicians Total Care, Inc.2009-06-23Not applicableUs
KetoprofenCapsule50 mg/1OralH.J. Harkins Company, Inc.2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1OralSTAT Rx USA LLC2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1Oralbryant ranch prepack2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1OralRebel Distributors Corp2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1OralNu Care Pharmaceuticals, Inc.1993-01-01Not applicableUs
KetoprofenCapsule75 mg/1OralMylan Pharmaceuticals Inc.1997-01-15Not applicableUs
KetoprofenCapsule75 mg/1OralPd Rx Pharmaceuticals, Inc.2011-01-18Not applicableUs
KetoprofenCapsule75 mg/1OralA S Medication Solutions Llc1993-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vopac - Ketoprofen, Lidocaine Hydrochloride PacKitSircle Laboratories, Llc2015-03-01Not applicableUs
International Brands
NameCompany
ActronNot Available
AlrheumunTeofarma
CapistenKissei
EpatecZeria Shinyaku
FastumMenarini
MenaminDaiko Seiyaku
OrudisAbbott
Orudis KTSanofi
OrugesicSanofi
OruvailWyeth
OscorelSanofi
ProfenidSanofi
ToprecSanofi
Brand mixturesNot Available
SaltsNot Available
Categories
UNII90Y4QC304K
CAS number22071-15-4
WeightAverage: 254.2806
Monoisotopic: 254.094294314
Chemical FormulaC16H14O3
InChI KeyDKYWVDODHFEZIM-UHFFFAOYSA-N
InChI
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
IUPAC Name
2-(3-benzoylphenyl)propanoic acid
SMILES
CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Pharmacology
IndicationFor symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Structured Indications
PharmacodynamicsKetoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
Mechanism of actionThe anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
C-X-C chemokine receptor type 1Proteinunknown
other
HumanP25024 details
Related Articles
AbsorptionKetoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Volume of distributionNot Available
Protein binding99% bound, primarily to albumin
Metabolism

Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

SubstrateEnzymesProduct
Ketoprofen
Not Available
Ketoprofen glucuronideDetails
Route of eliminationIn a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
Half lifeConventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

Clearance
  • Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
  • Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
  • 0.08 L/kg/h
  • 0.7 L/kg/h [alcoholic cirrhosis patients]
ToxicityLD50=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.

Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ketoprofen Action PathwayDrug actionSMP00085
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabKetoprofen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Ketoprofen can be decreased when combined with Abiraterone.Approved
AcebutololKetoprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Aceclofenac.Approved
AcenocoumarolKetoprofen may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ketoprofen.Approved, Vet Approved
AclarubicinKetoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ketoprofen.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.Approved
AliskirenKetoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololKetoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Amcinonide.Approved
AmikacinKetoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideKetoprofen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Ketoprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ketoprofen.Approved
AmrubicinKetoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodKetoprofen may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Anisodamine.Investigational
annamycinKetoprofen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine.Approved
Antithrombin III humanKetoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Ketoprofen may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanKetoprofen may increase the anticoagulant activities of Apixaban.Approved
ApramycinKetoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Ketoprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinKetoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinKetoprofen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanKetoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololKetoprofen may decrease the antihypertensive activities of Arotinolol.Approved
AtenololKetoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen.Approved
BalsalazideKetoprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminKetoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololKetoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketoprofen.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ketoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololKetoprofen may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Betulinic Acid.Investigational
BevantololKetoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketoprofen.Approved, Investigational
BisoprololKetoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinKetoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololKetoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Bucillamine.Investigational
BucindololKetoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Budesonide.Approved
BufuralolKetoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideKetoprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololKetoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketoprofen.Experimental
CapecitabineThe metabolism of Ketoprofen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Ketoprofen.Approved
CarbamazepineThe metabolism of Ketoprofen can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen.Approved, Vet Approved, Withdrawn
CarteololKetoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolKetoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Celecoxib.Approved, Investigational
CeliprololKetoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ketoprofen can be increased when it is combined with Ceritinib.Approved
CertoparinKetoprofen may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen.Approved
CholecalciferolThe metabolism of Ketoprofen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketoprofen.Approved
CinoxacinKetoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinKetoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidKetoprofen may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ketoprofen.Vet Approved
ClotrimazoleThe metabolism of Ketoprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Curcumin.Investigational
CyclosporineKetoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Ketoprofen can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with D-Limonene.Investigational
Dabigatran etexilateKetoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib.Approved
DalteparinKetoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidKetoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinKetoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Ketoprofen can be decreased when combined with Delavirdine.Approved
DesirudinKetoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketoprofen.Approved
DextranKetoprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ketoprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ketoprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ketoprofen may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen.Approved, Vet Approved
DicoumarolKetoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ketoprofen.Approved
DihydrostreptomycinKetoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketoprofen.Approved
DoxorubicinKetoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneKetoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Ketoprofen is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ebselen.Investigational
Edetic AcidKetoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanKetoprofen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Ketoprofen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketoprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketoprofen.Approved
EnoxacinKetoprofen may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinKetoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Epirizole.Approved
EpirubicinKetoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneKetoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilin.Approved
EsmololKetoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone sulfate.Approved
Etacrynic acidKetoprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen.Approved, Investigational
Ethyl biscoumacetateKetoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Ketoprofen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Ketoprofen is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ketoprofen.Vet Approved
FleroxacinKetoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ketoprofen.Approved, Withdrawn
FloxuridineThe metabolism of Ketoprofen can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with fluasterone.Investigational
FluconazoleThe metabolism of Ketoprofen can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fludrocortisone.Approved
FluindioneKetoprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineKetoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Ketoprofen can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ketoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Ketoprofen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ketoprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxKetoprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumKetoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketoprofen.Approved
FosphenytoinThe metabolism of Ketoprofen can be increased when combined with Fosphenytoin.Approved
FramycetinKetoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideKetoprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateKetoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinKetoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinKetoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketoprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Ketoprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinKetoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinKetoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinKetoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AKetoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinKetoprofen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Ketoprofen is combined with HE3286.Investigational
HeparinKetoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Higenamine.Investigational
HirulogKetoprofen may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Ketoprofen is combined with HMPL-004.Investigational
HydralazineKetoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen.Approved
Hygromycin BKetoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Icatibant.Approved
IdarubicinKetoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxKetoprofen may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ketoprofen.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen.Approved
IndenololKetoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Ketoprofen can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Indoprofen.Withdrawn
INNO-206Ketoprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Ketoprofen can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Istaroxime.Investigational
KanamycinKetoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Ketoprofen can be decreased when combined with Ketoconazole.Approved, Investigational
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen.Approved
LabetalolKetoprofen may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketoprofen.Approved, Investigational
LeflunomideThe metabolism of Ketoprofen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinKetoprofen may increase the anticoagulant activities of Lepirudin.Approved
LevobunololKetoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinKetoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Ketoprofen.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ketoprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Ketoprofen.Approved
LomefloxacinKetoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.Approved
LosartanThe metabolism of Ketoprofen can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Ketoprofen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketoprofen.Approved, Investigational
LumacaftorThe serum concentration of Ketoprofen can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Ketoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen.Approved
ME-609The risk or severity of adverse effects can be increased when Ketoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.Approved, Vet Approved
MesalazineKetoprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ketoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololKetoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.Approved
MetoprololKetoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideKetoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Ketoprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketoprofen.Approved
MometasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ketoprofen.Approved
MoxifloxacinKetoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nabumetone.Approved
NadololKetoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinKetoprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatKetoprofen may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ketoprofen.Approved
Nalidixic AcidKetoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 4016.Investigational
NeamineKetoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinKetoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinKetoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nepafenac.Approved
NetilmicinKetoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Ketoprofen can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nitroaspirin.Investigational
NorfloxacinKetoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinKetoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.Approved
OlsalazineKetoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Ketoprofen.Investigational
OmeprazoleThe metabolism of Ketoprofen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Orgotein.Vet Approved
OtamixabanKetoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.Approved
OxprenololKetoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Parecoxib.Approved
ParomomycinKetoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinKetoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinKetoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololKetoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateKetoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketoprofen.Approved
PhenindioneKetoprofen may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Ketoprofen can be increased when combined with Phenobarbital.Approved
PhenprocoumonKetoprofen may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen.Approved, Vet Approved
PhenytoinThe metabolism of Ketoprofen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen.Approved, Investigational
PindololKetoprofen may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinKetoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideKetoprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.Approved, Investigational
PlicamycinKetoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketoprofen.Approved
PractololKetoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Ketoprofen.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Ketoprofen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ketoprofen can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Propacetamol.Approved
PropranololKetoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ketoprofen.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Ketoprofen.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ketoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Ketoprofen.Vet Approved
Protein CKetoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanKetoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeKetoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinKetoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Ketoprofen is combined with PTC299.Investigational
PuromycinKetoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Ketoprofen can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen.Approved
QuinineThe metabolism of Ketoprofen can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketoprofen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.Experimental, Investigational
ReviparinKetoprofen may increase the anticoagulant activities of Reviparin.Approved
RibostamycinKetoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Ketoprofen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ketoprofen can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanKetoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinKetoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Ketoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ketoprofen.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ketoprofen.Investigational
SecobarbitalThe metabolism of Ketoprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Ketoprofen can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinKetoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Ketoprofen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolKetoprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CKetoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinKetoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinKetoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketoprofen.Approved
SpironolactoneKetoprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Ketoprofen is combined with SRT501.Investigational
StreptomycinKetoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinKetoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Ketoprofen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Ketoprofen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineKetoprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Ketoprofen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen.Approved
SulodexideKetoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Ketoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen.Approved, Withdrawn
TacrolimusKetoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Ketoprofen.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Ketoprofen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ketoprofen.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen.Approved, Investigational
TemafloxacinKetoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketoprofen.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Ketoprofen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ketoprofen can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiludronate.Approved, Vet Approved
TimololKetoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tixocortol.Approved
TobramycinKetoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Ketoprofen can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen.Approved
TorasemideKetoprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ketoprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneKetoprofen may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
TrimethoprimThe metabolism of Ketoprofen can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Trisalicylate-choline.Approved
TrovafloxacinKetoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketoprofen.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Ketoprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinKetoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Ketoprofen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Ketoprofen.Approved
VoriconazoleThe metabolism of Ketoprofen can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinKetoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranKetoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Ketoprofen may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Ketoprofen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ketoprofen.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zomepirac.Withdrawn
ZorubicinKetoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected.
  • Take with food to reduce gastric irritation.
References
Synthesis Reference

Attilio Citterio, Daniele Fancelli, “Method of preparing ketoprofen.” U.S. Patent US4845281, issued December, 1982.

US4845281
General References
  1. Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [PubMed:3526298 ]
  2. Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [PubMed:16274258 ]
External Links
ATC CodesM01AE53M02AA10M01AE03
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (160 KB)
MSDSDownload (75.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7132
P-glycoprotein inhibitor INon-inhibitor0.9168
P-glycoprotein inhibitor IINon-inhibitor0.9589
Renal organic cation transporterNon-inhibitor0.8818
CYP450 2C9 substrateNon-substrate0.7183
CYP450 2D6 substrateNon-substrate0.9598
CYP450 3A4 substrateNon-substrate0.7685
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9604
CYP450 2C19 inhibitorNon-inhibitor0.9465
CYP450 3A4 inhibitorNon-inhibitor0.9598
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9438
Ames testNon AMES toxic0.9801
CarcinogenicityNon-carcinogens0.6299
BiodegradationReady biodegradable0.6701
Rat acute toxicity2.2378 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9661
hERG inhibition (predictor II)Non-inhibitor0.9595
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Elan pharmaceutical research corp
  • Mylan pharmaceuticals inc
  • Watson laboratories inc florida
  • Wyeth pharmaceuticals inc
  • Heritage pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wyeth ayerst laboratories
  • Novartis consumer health inc
  • Bayer healthcare llc
  • L perrigo co
  • Wyeth consumer healthcare
Packagers
Dosage forms
FormRouteStrength
CapsuleOral50 mg/1
CapsuleOral50 mg
CapsuleOral75 mg/1
Capsule, extended releaseOral200 mg/1
TabletOral75 mg/1
Tablet, extended releaseOral200 mg
Tablet, delayed releaseOral100 mg
Tablet, delayed releaseOral50 mg
Capsule, extended releaseOral150 mg
Capsule, extended releaseOral200 mg
SuppositoryRectal100 mg
SuppositoryRectal50 mg
Kit
Prices
Unit descriptionCostUnit
Ketoprofen powder43.74USD g
Ketoprofen micronized powder3.84USD g
Ketoprofen CR 200 mg 24 Hour Capsule2.8USD capsule
Orudis 75 mg capsule1.58USD capsule
Apo-Keto Sr 200 mg Sustained-Release Tablet1.46USD tablet
Ketoprofen 75 mg capsule1.12USD capsule
Pms-Ketoprofen 100 mg Suppository1.1USD suppository
Ketoprofen 50 mg capsule1.0USD capsule
Apo-Keto-E 100 mg Enteric-Coated Tablet0.71USD tablet
Apo-Keto 50 mg Capsule0.35USD capsule
Apo-Keto-E 50 mg Enteric-Coated Tablet0.35USD tablet
Orudis kt 12.5 mg tablet0.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point94 °CU.S. Patent 3,641,127.
water solubility51 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.12SANGSTER (1993)
logS-3.7ADME Research, USCD
pKa4.45SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0213 mg/mLALOGPS
logP3.29ALOGPS
logP3.61ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.52 m3·mol-1ChemAxon
Polarizability26.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • 2-phenylpropanoic-acid
  • Phenylacetate
  • Acetophenone
  • Aryl ketone
  • Benzoyl
  • Ketone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Parsadaniantz SM, Lebeau A, Duval P, Grimaldi B, Terlain B, Kerdelhue B: Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol. 2000 Aug;12(8):766-73. [PubMed:10929089 ]
  2. Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5. [PubMed:11811354 ]
  3. Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718 ]
  4. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823 ]
  5. Levoin N, Blondeau C, Guillaume C, Grandcolas L, Chretien F, Jouzeau JY, Benoit E, Chapleur Y, Netter P, Lapicque F: Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen. Biochem Pharmacol. 2004 Nov 15;68(10):1957-69. [PubMed:15476667 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10. [PubMed:10895904 ]
  2. Sommerauer M, Ates M, Guhring H, Brune K, Amann R, Peskar BA: Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9. [PubMed:11729362 ]
  3. Levoin N, Chretien F, Lapicque F, Chapleur Y: Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7. [PubMed:11814865 ]
  4. Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718 ]
  5. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Interleukin-8 receptor activity
Specific Function:
Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity.
Gene Name:
CXCR1
Uniprot ID:
P25024
Molecular Weight:
39790.735 Da
References
  1. Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F: 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. [PubMed:15974585 ]
  2. Bizzarri C, Pagliei S, Brandolini L, Mascagni P, Caselli G, Transidico P, Sozzani S, Bertini R: Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem Pharmacol. 2001 Jun 1;61(11):1429-37. [PubMed:11331079 ]
  3. Wang LM, Toyoshima A, Mineshita S, Wang XX, Yamamoto T, Nomura Y, Yang L, Koikei Y, Shiba K, Honda Y: The anti-inflammatory effects of ketoprofen in animal experiments. Drugs Exp Clin Res. 1997;23(1):1-6. [PubMed:9093816 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C: Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. Chirality. 2001 Jul;13(7):372-8. [PubMed:11400191 ]
  2. Lagrange F, Penhourcq F, Matoga M, Bannwarth B: Binding of ketoprofen enantiomers in various human albumin preparations. J Pharm Biomed Anal. 2000 Oct;23(5):793-802. [PubMed:11022905 ]
  3. Li F, Zhou D, Guo X: Study on the protein binding of ketoprofen using capillary electrophoresis frontal analysis compared with liquid chromatography frontal analysis. J Chromatogr Sci. 2003 Mar;41(3):137-41. [PubMed:12725696 ]
  4. Zhou D, Li F: [Study of protein binding in ketoprofen using liquid chromatography frontal analysis in comparison with capillary electrophoresis frontal analysis]. Se Pu. 2004 Nov;22(6):601-4. [PubMed:15807110 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807 ]
  2. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697 ]
  5. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  2. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002 Oct;83(1):57-66. [PubMed:12358729 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
  2. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818 ]
  3. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23